Q3 2024 13F Holders as of 9/30/2024
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
19.6M
-
Number of holders
-
12
-
Total 13F shares, excl. options
-
2.42M
-
Shares change
-
+1.92M
-
Total reported value, excl. options
-
$581K
-
Value change
-
+$454K
-
Number of buys
-
7
-
Number of sells
-
-6
-
Price
-
$0.24
Significant Holders of Ensysce Biosciences, Inc. - Common Stock, par value $0.0001 per share (ENSC) as of Q3 2024
15 filings reported holding ENSC - Ensysce Biosciences, Inc. - Common Stock, par value $0.0001 per share as of Q3 2024.
Ensysce Biosciences, Inc. - Common Stock, par value $0.0001 per share (ENSC) has 12 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 2.42M shares
of 19.6M outstanding shares and own 12.35% of the company stock.
Largest 10 shareholders include SABBY MANAGEMENT, LLC (1.16M shares), Anson Funds Management LP (984K shares), UBS Group AG (113K shares), GEODE CAPITAL MANAGEMENT, LLC (46.1K shares), CITADEL ADVISORS LLC (23.6K shares), HRT FINANCIAL LP (23.6K shares), RENAISSANCE TECHNOLOGIES LLC (22.4K shares), Cerity Partners LLC (21.4K shares), VANGUARD GROUP INC (18.2K shares), and Tower Research Capital LLC (TRC) (6.45K shares).
This table shows the top 12 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.